Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Davidson Capital Management Inc.

Davidson Capital Management Inc. increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,672 shares of the company's stock after acquiring an additional 1,279 shares during the quarter. Davidson Capital Management Inc.'s holdings in Medpace were worth $3,213,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Medpace during the 4th quarter worth $30,000. Stone House Investment Management LLC acquired a new position in Medpace in the third quarter valued at $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the third quarter valued at $37,000. Capital Performance Advisors LLP acquired a new position in Medpace in the third quarter valued at $46,000. Finally, True Wealth Design LLC increased its stake in Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after purchasing an additional 168 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MEDP. Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. William Blair restated an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $381.44.

Medpace Stock Performance

MEDP stock traded down $2.24 during trading on Friday, reaching $340.17. 299,085 shares of the company were exchanged, compared to its average volume of 208,882. The company has a market cap of $10.57 billion, a P/E ratio of 29.79, a PEG ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The stock's 50 day moving average price is $343.70 and its 200 day moving average price is $348.83.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.